Investigating the effects of DMT on alcohol use disorder
The potential therapeutic effects of N, N-dimethyltryptamine (DMT) on alcohol use disorder (AUD)
This study is looking at whether a single dose of a psychedelic called DMT, combined with some therapy, can help people who are having trouble with alcohol use, and it will check how safe and well-tolerated DMT is during the process.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10904027 on NIH RePORTER |
What this research studies
This research explores the potential therapeutic effects of N,N-dimethyltryptamine (DMT), a psychedelic compound, on individuals struggling with alcohol use disorder (AUD). Participants will receive either a single dose of intravenous DMT or a placebo, alongside a brief course of psychotherapy. The study aims to assess changes in alcohol consumption and the overall safety and tolerability of DMT through various monitoring methods. By examining the acute effects of DMT, the research seeks to provide insights into its efficacy as a treatment for AUD.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with moderate to severe alcohol use disorder who are not currently seeking treatment.
Not a fit: Patients who are not diagnosed with alcohol use disorder or those who are actively seeking treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could offer a novel treatment option for individuals with alcohol use disorder, potentially reducing their alcohol consumption and improving their quality of life.
How similar studies have performed: Preliminary evidence from observational and animal studies suggests that psychedelic compounds like DMT may have therapeutic potential, indicating that this approach is promising but still relatively novel.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Bassir Nia, Anahita — Yale University
- Study coordinator: Bassir Nia, Anahita
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.